Menu

  • Cardiac Diagnostics & Monitoring
  • Conditions
  • Clinical Evidence
  • Resources
  • Reimbursement

    • The REVEAL AF study1

    The REVEAL AF study demonstrates the need for continuous, long-term monitoring with the Reveal LINQ™ ICM in patients at high risk for AF and stroke.

    Study design1

    • Prospective, global, multicenter study
    • 446 patients enrolled, 385 patients received a Reveal™ ICM and were included in the analysis cohort
    • Patients were followed for an average of 22.5 months + 7.7 months.

    Patient inclusion criteria

    A CHADS2 score of greater than or equal to 3 or CHADS2 = 2 and at least one of the following:

    • Coronary artery disease
    • Renal impairment (GFR 30–60 ml/min)
    • Sleep apnea
    • Chronic obstructive pulmonary disease
    • No AF found after 24 hours of cardiac monitoring

    End points

    Primary

    Determine the incidence rate of AF lasting greater than or equal to six minutes in patients who are at high risk of having AF and stroke.

    Secondary

    • Identify predictors of AF onset
    • Characterize the timing and nature of clinical actions relative to detection of AF

    Key findings1

    Detection rate of patients with AF of greater than or equal to six minutes in duration1

    40%

    AF detection rate in high-risk patients at 30 months

     

    123 days

    was the median time to AF detection in high-risk patients.

    84.5%

    of patients with AF would have been missed if only monitored for 30 days.

    Inform your clinical decisions.1

    There was no significant difference in detection rates between patients with CHADS2 2, 3, and 4 or more.

    AF incidence by CHADS2 subgroup1

    Clinical impact: more appropriate care1

    AF detected
    through Reveal LINQ™ ICM was found to be actionable by physicians.

    56.3%

    of patients were prescribed oral anticoagulants during follow-up.

    14.8%

    of patients were prescribed rhythm-control medication during follow-up.

    Related products